On 1 November 2026 the Australian government announced that the Pharmaceutical Benefits Scheme would be extended to include a child‑friendly granule form of Trikafta for cystic fibrosis, a new treatment for thyroid eye disease, a wider role for Adcetris in blood cancer and larger quantities of the cholesterol medicine Repatha. Health Minister Mark Butler said the changes would lift the financial burden on patients and expand access to medicines that were previously too expensive or unavailable under the PBS.
Under the new listing, children aged six to 11 who weigh less than 30 kg and are diagnosed with cystic fibrosis will qualify for a granule version of Trikafta, which targets the underlying genetic defect that causes the disease. The government estimates that about 3,300 Australians will benefit from the broadened listing each year. Without the PBS subsidy, a single prescription could cost more than 20,300 Australian dollars (approximately 14,200 U.S. dollars). The child‑friendly formulation is designed to help children who have difficulty swallowing tablets.
For thyroid eye disease, the PBS now lists Tepezza as a treatment for active, moderate‑to‑severe cases. Australian health officials expect that around 310 people will be eligible for the medication annually, providing a new hope for those suffering from eye complications often associated with Graves’ disease.
The changes also expand subsidised access to the biologic drug Adcetris, giving patients with advanced CD30‑positive classical Hodgkin lymphoma a first‑line treatment option that was previously only available through specialist pathways. The scheme will now support roughly 370 Australians each year, according to the Minister’s statement.
In addition, the PBS has amended the dispensing limits for Repatha, a medication used to treat high cholesterol. The amendment is part of the government’s 60‑day prescription initiative, which allows eligible patients to obtain larger quantities of the drug at once. Under the new arrangement, patients will pay a maximum of 25 Australian dollars per prescription, or 7.70 Australian dollars for concession card holders, thereby lowering ongoing costs for long‑term users.
These updates are part of a broader federal effort that has seen the government approve 511 new and amended PBS listings since July 2022. The expanded catalogue aims to improve equity in access to high‑cost treatments and reduce the financial strain on families caring for chronic or life‑threatening conditions.
Health advocates say the revisions demonstrate a commitment to public accountability by ensuring that essential medicines are made affordable through a transparent, government‑run subsidy program. Patients and their families now have a more predictable pathway to receive lifesaving treatments, as the PBS provides a capped out‑of‑pocket maximum for each drug.
Critics, however, point out that the PBS remains voluntary for many private insurers and that some patients may still face coverage gaps or high co‑payments under existing health plans. Moreover, the demand for the new listings could strain public funding if enrolment exceeds the projected numbers, potentially affecting the long‑term sustainability of the PBS.
The Australian Senate has scheduled a review of the PBS funding model to address these concerns, exploring adjustments that would balance broader access with fiscal responsibility. Meanwhile, patient groups have welcomed the immediate relief provided by the new drug listings, noting that the changes align with international best practice in subsidised medicine delivery.
As the PBS updates take effect, patients, clinicians and policymakers will monitor the impact on treatment uptake, health outcomes and public expenditure. The government’s promise of additional funding for future PBS reforms positions Australia to respond adaptively to evolving medical and economic landscapes.
